We are live on ! Find out more
RVPHW

Reviva Pharmaceuticals Warrants
RVPHW

Delisted

RVPHW was delisted on the 12th of December, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Reviva Pharmaceuticals Warrants in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.25% less ownership

Funds ownership: 2.25% → 0% (-2.3%)

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $12.8K → $0 (-$12.8K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$10.8K
2
VF
Virtu Financial
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
– -$10.8K -134,668 Closed
VF
2
Virtu Financial
New York
– -$2K -20,383 Closed

RVPHW Hedge Fund Activity: Q4 2025 in Review

0 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q4 2025, worth a combined $0 — down 100% from $12.8K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RVPHW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $10.8K sold.

  • 0 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q4 2025, down from 2 in Q3 2025.
  • Funds reported $0 of Reviva Pharmaceuticals Warrants stock for Q4 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q4 2025 and 2 closed out, a net change of -2 holders.
  • The largest Reviva Pharmaceuticals Warrants seller in Q4 2025 was Susquehanna International Group, an estimated $10.8K sold.

Based on aggregated 13F filings for Q4 2025.